Cholecystokinin receptors in GtoPdb v.2023.1 Cholecystokinin receptors in GtoPdb v.2023.1

Abstract Cholecystokinin receptors ( nomenclature as agreed by the nomenclature as agreed by the NC-IUPHARNC-IUPHAR Subcommittee on CCK receptors Subcommittee on CCK receptors [[9090]] ) are activated by the endogenous peptides cholecystokinin-8 (CCK-8), CCK-33, CCK-58 and gastrin (gastrin-17). There are only two distinct subtypes of CCK receptors, CCK 1 and CCK 2 receptors [64, 124], with some alternatively spliced forms most often identified in neoplastic cells. The CCK receptor subtypes are distinguished by their peptide selectivity, with the CCK 1 receptor requiring the carboxyl-terminal heptapeptide-amide that includes a sulfated tyrosine for high affinity and potency, while the CCK 2 receptor requires only the carboxyl-terminal tetrapeptide shared by each CCK and gastrin peptides. These receptors have characteristic and distinct distributions, with both present in both the central nervous system and peripheral tissues.

[1]  Peter Buneman,et al.  Why data citation isn't working, and what to do about it , 2020, Database J. Biol. Databases Curation.

[2]  A. Johnston,et al.  Single oral doses of netazepide (YF476), a gastrin receptor antagonist, cause dose‐dependent, sustained increases in gastric pH compared with placebo and ranitidine in healthy subjects , 2012, Alimentary pharmacology & therapeutics.

[3]  J. Pyati,et al.  JNJ-26070109 [(R)4-Bromo-N-[1-(2,4-difluoro-phenyl)-ethyl]-2-(quinoxaline-5-sulfonylamino)-benzamide]: A Novel, Potent, and Selective Cholecystokinin 2 Receptor Antagonist with Good Oral Bioavailability , 2011, Journal of Pharmacology and Experimental Therapeutics.

[4]  A. Kalgutkar,et al.  Discovery of N-benzyl-2-[(4S)-4-(1H-indol-3-ylmethyl)-5-oxo-1-phenyl-4,5-dihydro-6H-[1,2,4]triazolo[4,3-a][1,5]benzodiazepin-6-yl]-N-isopropylacetamide, an orally active, gut-selective CCK1 receptor agonist for the potential treatment of obesity. , 2010, Bioorganic & medicinal chemistry letters.

[5]  S. Rasmussen,et al.  Structure of a nanobody-stabilized active state of the β2 adrenoceptor , 2010, Nature.

[6]  L. Miller,et al.  Synthesis and in vitro characterization of radioiodinatable benzodiazepines selective for type 1 and type 2 cholecystokinin receptors. , 2009, Journal of medicinal chemistry.

[7]  L. Miller,et al.  Use of N,O-bis-Fmoc-D-Tyr-ONSu for introduction of an oxidative iodination site into cholecystokinin family peptides. , 2009, International journal of peptide and protein research.

[8]  S. Watson,et al.  Effect of Z-360, a novel orally active CCK-2/gastrin receptor antagonist on tumor growth in human pancreatic adenocarcinoma cell lines in vivo and mode of action determinations in vitro , 2008, Cancer Chemotherapy and Pharmacology.

[9]  R. Jensen,et al.  Progress in developing cholecystokinin (CCK)/gastrin receptor ligands that have therapeutic potential. , 2007, Current opinion in pharmacology.

[10]  J. Pyati,et al.  3-[5-(3,4-Dichloro-phenyl)-1-(4-methoxy-phenyl)-1H-pyrazol-3-yl]-2-m-tolyl-propionate (JNJ-17156516), a Novel, Potent, and Selective Cholecystokinin 1 Receptor Antagonist: In Vitro and in Vivo Pharmacological Comparison with Dexloxiglumide , 2007, Journal of Pharmacology and Experimental Therapeutics.

[11]  C. Knauf,et al.  Involvement of cholecystokinin 2 receptor in food intake regulation: hyperphagia and increased fat deposition in cholecystokinin 2 receptor-deficient mice. , 2007, Endocrinology.

[12]  A. Kolokoltsov,et al.  Constitutively active CCK2 receptor splice variant increases Src-dependent HIF-1α expression and tumor growth , 2007, Oncogene.

[13]  A. Kopin,et al.  Targeted disruption of the murine CCK1 receptor gene reduces intestinal lipid-induced feedback inhibition of gastric function. , 2006, American journal of physiology. Gastrointestinal and liver physiology.

[14]  R. Ritter,et al.  Reduced CCK-induced Fos expression in the hindbrain, nodose ganglia, and enteric neurons of rats lacking CCK-1 receptors , 2005, Brain Research.

[15]  L. Miller,et al.  Differential docking of high-affinity peptide ligands to type A and B cholecystokinin receptors demonstrated by photoaffinity labeling. , 2005, Biochemistry.

[16]  J. Seo,et al.  Pharmacological characterization of rebamipide: its cholecystokinin CCK1 receptor binding profile and effects on Ca2+ mobilization and amylase release in rat pancreatic acinar cells. , 2004, European journal of pharmacology.

[17]  J. Bartolomé-Nebreda,et al.  Pharmacological Study of IQM-97,423, a Potent and Selective CCK1 Receptor Antagonist with Protective Effect in Experimental Acute Pancreatitis , 2004, Pharmacology.

[18]  F. Schmitz,et al.  Targeted disruption of the murine cholecystokinin-1 receptor promotes intestinal cholesterol absorption and susceptibility to cholesterol cholelithiasis. , 2004, The Journal of clinical investigation.

[19]  G. Mazzocchi,et al.  Cholecystokinin (CCK) stimulates aldosterone secretion from human adrenocortical cells via CCK2 receptors coupled to the adenylate cyclase/protein kinase A signaling cascade. , 2004, The Journal of clinical endocrinology and metabolism.

[20]  J. Morisset,et al.  Localization of Cholecystokinin Receptor Subtypes in the Endocine Pancreas , 2003, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[21]  D. Segal,et al.  Altered extracellular dopamine concentration in the brains of cholecystokinin-A receptor deficient rats , 2003, Neuroscience Letters.

[22]  H. Friess,et al.  Distribution of CCK1 and CCK2 receptors in normal and diseased human pancreatic tissue. , 2003, Gastroenterology.

[23]  F. Makovec,et al.  Anthranilic acid derivatives: a new class of non-peptide CCK1 receptor antagonists. , 2003, Bioorganic & medicinal chemistry.

[24]  I. Zagon,et al.  Characterization of the CCK-C (cancer) receptor in human pancreatic cancer. , 2002, International journal of molecular medicine.

[25]  D. Keire,et al.  Differences in Receptor Binding and Stability to Enzymatic Digestion Between CCK-8 and CCK-58 , 2002, Pancreas.

[26]  J. Rehfeld,et al.  Differentiation of gastric ECL cells is altered in CCK(2) receptor-deficient mice. , 2002, Gastroenterology.

[27]  L. Miller,et al.  A misspliced form of the cholecystokinin-B/gastrin receptor in pancreatic carcinoma: role of reduced sellular U2AF35 and a suboptimal 3'-splicing site leading to retention of the fourth intron. , 2002, Cancer research.

[28]  I. Murata,et al.  Increased Gastric Acid Secretion in Cholecystokinin-1 Receptor-Deficient Otsuka Long-Evans Tokushima Fatty Rats , 2002, Scandinavian journal of gastroenterology.

[29]  F. Schmitz,et al.  Cellular expression of CCK-A and CCK-B/gastrin receptors in human gastric mucosa , 2001, Regulatory Peptides.

[30]  B. Ji,et al.  Human pancreatic acinar cells lack functional responses to cholecystokinin and gastrin. , 2001, Gastroenterology.

[31]  B. Roques,et al.  Behavioral Profile of CCK2 Receptor-deficient Mice , 2001, Neuropsychopharmacology.

[32]  J. Reubi,et al.  Localization and characterization of neuropeptide receptors in human colon , 2001, Naunyn-Schmiedeberg's Archives of Pharmacology.

[33]  F. Schmitz,et al.  Identification of CCK-B/gastrin receptor splice variants in human peripheral blood mononuclear cells , 2001, Regulatory Peptides.

[34]  T. Hökfelt,et al.  Expression and regulation of cholecystokinin and cholecystokinin receptors in rat nodose and dorsal root ganglia , 2001, Brain Research.

[35]  H. Hellmich,et al.  Human Colorectal Cancers Express a Constitutively Active Cholecystokinin-B/Gastrin Receptor That Stimulates Cell Growth* , 2000, The Journal of Biological Chemistry.

[36]  A. Capelli,et al.  Synthesis and SAR of new 5-phenyl-3-ureido-1,5-benzodiazepines as cholecystokinin-B receptor antagonists. , 2000, Journal of medicinal chemistry.

[37]  P. Ferrara,et al.  The agonist SR 146131 and the antagonist SR 27897 occupy different sites on the human CCK(1) receptor. , 2000, European journal of pharmacology.

[38]  F. Fahrenholz,et al.  Expression and cell-specific localization of the cholecystokinin B/gastrin receptor in the human stomach , 2000, Cell and Tissue Research.

[39]  J. Crawley,et al.  International Union of Pharmacology. XXI. Structure, distribution, and functions of cholecystokinin receptors. , 1999, Pharmacological reviews.

[40]  N. Tarasova,et al.  Evidence for a functional role of the cholecystokinin-B/gastrin receptor in the human fetal and adult pancreas. , 1999, Diabetes.

[41]  B. Roques,et al.  Rat Hippocampal Neurons Are Critically Involved in Physiological Improvement of Memory Processes Induced by Cholecystokinin-B Receptor Stimulation , 1999, The Journal of Neuroscience.

[42]  H. Ellenberger,et al.  Sulfated cholecystokinin octapeptide in the rat: pontomedullary distribution and modulation of the respiratory pattern. , 1999, Canadian journal of physiology and pharmacology.

[43]  S. Nomoto,et al.  Impaired Learning and Memory in OLETF Rats Without Cholecystokinin (CCK)-A Receptor , 1999, Physiology & Behavior.

[44]  J. Laissue,et al.  Receptor autoradiographic evaluation of cholecystokinin, neurotensin, somatostatin and vasoactive intestinal peptide receptors in gastro‐intestinal adenocarcinoma samples: Where are they really located? , 1999, International journal of cancer.

[45]  P. Soubrié,et al.  SR146131: a new potent, orally active, and selective nonpeptide cholecystokinin subtype 1 receptor agonist. I. In vitro studies. , 1999, The Journal of pharmacology and experimental therapeutics.

[46]  J. Simiand,et al.  SR146131: a new potent, orally active, and selective nonpeptide cholecystokinin subtype 1 receptor agonist. II. In vivo pharmacological characterization. , 1999, The Journal of pharmacology and experimental therapeutics.

[47]  E. Lindström,et al.  Pharmacological analysis of CCK2 receptor antagonists using isolated rat stomach ECL cells , 1999, British journal of pharmacology.

[48]  M. Impicciatore,et al.  Characterization of antisecretory and antiulcer activity of CR 2945, a new potent and selective gastrin/CCK(B) receptor antagonist. , 1999, European journal of pharmacology.

[49]  J. Black,et al.  Characterization of the binding of a novel radioligand to CCKB/gastrin receptors in membranes from rat cerebral cortex , 1999, British journal of pharmacology.

[50]  M. E. Pierson,et al.  ARL 15849: A Selective CCK-A Agonist With Anorectic Activity in the Rat and Dog , 1998, Pharmacology Biochemistry and Behavior.

[51]  N. Vaysse,et al.  Differential expression of the CCK‐A and CCK‐B/gastrin receptor genes in human cancers of the esophagus, stomach and colon , 1997, International journal of cancer.

[52]  M. K. James,et al.  Optimization of 3-(1H-indazol-3-ylmethyl)-1,5-benzodiazepines as potent, orally active CCK-A agonists. , 1997, Journal of medicinal chemistry.

[53]  J. M. Lay,et al.  Molecular structure of the mouse CCK-A receptor gene. , 1997, Biochemical and biophysical research communications.

[54]  P. Cuq,et al.  mRNAs encoding CCKB but not CCKA receptors are expressed in human T lymphocytes and Jurkat lymphoblastoid cells. , 1997, Life sciences.

[55]  D. Thompson,et al.  Characterization of cholecystokininA and cholecystokininB receptors expressed by vagal afferent neurons , 1997, Neuroscience.

[56]  A. Nishida,et al.  (3R)-N-(1-(tert-Butylcarbonylmethyl)-2,3-dihydro-2-oxo-5-(2-pyridyl)- 1H-1,4-benzodiazepin-3-yl)-N′-(3(methylamino)phenyl)urea (YF476): A Potent and Orally Active Gastrin/CCK-B Antagonist. , 1997 .

[57]  T. Willson,et al.  Discovery of 1,5‐Benzodiazepines with Peripheral Cholecystokinin (CCK‐ A) Receptor Agonist Activity (II): Optimization of the C3 Amino Substituent. , 1997 .

[58]  H. Friess,et al.  Localization of cholecystokinin A and cholecystokinin B-gastrin receptors in the human stomach. , 1997, Gastroenterology.

[59]  A. Funakoshi,et al.  Mouse cholecystokinin type-A receptor gene and its structural analysis. , 1997, Gene.

[60]  A. Nishida,et al.  YF476 is a new potent and selective gastrin/cholecystokinin‐B receptor antagonist in vitro and in vivo , 1997, Alimentary pharmacology & therapeutics.

[61]  T. Noda,et al.  G protein-coupled cholecystokinin-B/gastrin receptors are responsible for physiological cell growth of the stomach mucosa in vivo. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[62]  B K Trivedi,et al.  Cholecystokinin B antagonists. Synthesis and quantitative structure-activity relationships of a series of C-terminal analogues of CI-988. , 1996, Bioorganic & medicinal chemistry.

[63]  N. Brammer,et al.  Pharmacological characterization of a Chinese hamster ovary cell line transfected with the human CCK-B receptor gene , 1996, Neuropeptides.

[64]  C. Lamers,et al.  Cholecystokinin receptors in human pancreas and gallbladder muscle: A comparative study , 1996, Regulatory Peptides.

[65]  H. Taniguchi,et al.  Pharmacological profile of T-0632, a novel potent and selective CCKA receptor antagonist, in vitro. , 1996, European journal of pharmacology.

[66]  R. Håkanson,et al.  Cholecystokinin-A and cholecystokinin-B/gastrin receptor mRNA expression in the gastrointestinal tract and pancreas of the rat and man. A polymerase chain reaction study. , 1996, Scandinavian journal of gastroenterology.

[67]  M. Otsuki,et al.  Pharmacological profile of TP‐680, a new cholecystokininA receptor antagonist , 1996, British journal of pharmacology.

[68]  H. Broughton,et al.  Controlled modification of acidity in cholecystokinin B receptor antagonists: N-(1,4-benzodiazepin-3-yl)-N'-[3-(tetrazol-5-ylamino) phenyl]ureas. , 1996, Journal of medicinal chemistry.

[69]  M. K. James,et al.  Discovery of 1,5-benzodiazepines with peripheral cholecystokinin (CCK-A) receptor agonist activity. 1. Optimization of the agonist "trigger". , 1996, Journal of medicinal chemistry.

[70]  B. Roques,et al.  His381 of the rat CCKB receptor is essential for CCKB versus CCKA receptor antagonist selectivity. , 1996, European journal of pharmacology.

[71]  G. Woodruff,et al.  Peptoid CCK receptor antagonists: pharmacological evaluation of CCKA, CCKB and mixed receptor antagonists , 1995, European Journal of Pharmacology.

[72]  J. Hunter,et al.  Synthesis of novel iodinated radioligands with high affinity and selectivity for CCK-B/gastrin receptors , 1995 .

[73]  E. Wieben,et al.  Abnormal processing of the human cholecystokinin receptor gene in association with gallstones and obesity. , 1995, Gastroenterology.

[74]  N. Vaysse,et al.  Identification of a region of the N-terminal of the human CCKA receptor essential for the high affinity interaction with agonist CCK. , 1995, Biochemical and biophysical research communications.

[75]  A. Funakoshi,et al.  Gene structure of rat cholecystokinin type-A receptor. , 1995, Biochemical and biophysical research communications.

[76]  B. Roques,et al.  The transfer of rats from a familiar to a novel environment prolongs the increase of extracellular dopamine efflux induced by CCK8 in the posterior nucleus accumbens , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[77]  S. Iversen,et al.  Biological properties of the benzodiazepine amidine derivative L-740,093, a cholecystokinin-B/gastrin receptor antagonist with high affinity in vitro and high potency in vivo. , 1994, Molecular pharmacology.

[78]  B. Ducos,et al.  Pharmacological properties of ureido-acetamides, new potent and selective non-peptide CCKB/gastrin receptor antagonists. , 1994, European journal of pharmacology.

[79]  D. Yule,et al.  Characterization of cholecystokininA receptor agonist activity by a family of cholecystokininB receptor antagonists. , 1994, The Journal of pharmacology and experimental therapeutics.

[80]  A. Nishida,et al.  Pharmacological profile of (R)-1-[2,3-dihydro-1-(2'-methylphenacyl)-2-oxo- 5-phenyl-1H-1,4-benzodiazepin-3-yl]-3-(3-methylphenyl)urea (YM022), a new potent and selective gastrin/cholecystokinin-B receptor antagonist, in vitro and in vivo. , 1994, The Journal of pharmacology and experimental therapeutics.

[81]  S. Wank,et al.  Molecular Cloning, Functional Expression, and Chromosomal Localization of the Human Cholecystokinin Type A Receptor , 1994, Biochemical and biophysical research communications.

[82]  M. Kadowaki,et al.  Pharmacological profile of FK480, a novel cholecystokinin type-A receptor antagonist: comparison to loxiglumide. , 1994, The Journal of pharmacology and experimental therapeutics.

[83]  C. Logsdon,et al.  Both low- and high-affinity CCK receptor states mediate trophic effects on rat pancreatic acinar cells. , 1993, The American journal of physiology.

[84]  T. Yamada,et al.  The human gastrin/cholecystokinin type B receptor gene: alternative splice donor site in exon 4 generates two variant mRNAs. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[85]  M. Ito,et al.  Functional characterization of a human brain cholecystokinin-B receptor. A trophic effect of cholecystokinin and gastrin. , 1993, The Journal of biological chemistry.

[86]  M. Arisawa,et al.  Species specificity of pharmacological characteristics of CCK-B receptors , 1993, Neuroscience Letters.

[87]  L. Miller,et al.  Molecular cloning and functional expression of the human gallbladder cholecystokinin A receptor. , 1993, Biochemical and biophysical research communications.

[88]  L. F. Kolakowski,et al.  The human brain cholecystokinin-B/gastrin receptor. Cloning and characterization. , 1993, The Journal of biological chemistry.

[89]  G. Woodruff,et al.  [3H]PD 140376: a novel and highly selective antagonist radioligand for the cholecystokininB/gastrin receptor in guinea pig cerebral cortex and gastric mucosa. , 1993, Molecular pharmacology.

[90]  D. Rees,et al.  Cholecystokinin dipeptoid antagonists: design, synthesis, and anxiolytic profile of some novel CCK-A and CCK-B selective and "mixed" CCK-A/CCK-B antagonists. , 1993, Journal of medicinal chemistry.

[91]  D. Gully,et al.  Peripheral biological activity of SR 27897: a new potent non-peptide antagonist of CCKA receptors. , 1993, European journal of pharmacology.

[92]  C. Esquivel,et al.  Characterization of cholecystokinin receptors on the human gallbladder. , 1993, Surgery.

[93]  S. Leach,et al.  Characterization of cAMP‐dependent protein kinase activation by CCK in rat pancreas , 1993, FEBS letters.

[94]  S. Wank,et al.  Molecular cloning of the human brain and gastric cholecystokinin receptor: structure, functional expression and chromosomal localization. , 1992, Biochemical and biophysical research communications.

[95]  P. Corringer,et al.  [Study of induced effects by selective CCKB agonists cholecystokinin in the nociception and behavior in rodents]. , 1992, Therapie.

[96]  D. Flynn,et al.  1,3,4-trisubstituted pyrrolidinones as scaffolds for construction of peptidomimetic cholecystokinin antagonists , 1992 .

[97]  A. Weerth,et al.  The brain and gastrointestinal cholecystokinin receptor family; structure and functional expression , 1992, Regulatory Peptides.

[98]  L. Bednarz,et al.  Behavioral effects of A71623, a highly selective CCK-A agonist tetrapeptide. , 1992, The American journal of physiology.

[99]  P. Corringer,et al.  [3H]pBC 264, a suitable probe for studying cholecystokinin-B receptors: binding characteristics in rodent brains and comparison with [3H]SNF 8702. , 1992, Molecular pharmacology.

[100]  L. F. Kolakowski,et al.  Expression cloning and characterization of the canine parietal cell gastrin receptor. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[101]  R. Jensen,et al.  Purification, molecular cloning, and functional expression of the cholecystokinin receptor from rat pancreas. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[102]  B. Costall,et al.  Development of a class of selective cholecystokinin type B receptor antagonists having potent anxiolytic activity. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[103]  M. Galas,et al.  Cyclic cholecystokinin analogues that are highly selective for rat and guinea pig central cholecystokinin receptors. , 1990, Molecular pharmacology.

[104]  S. Iversen,et al.  Evidence that decreased feeding induced by systemic injection of cholecystokinin is mediated by CCK-A receptors. , 1989, European journal of pharmacology.

[105]  D. Daugherty,et al.  Posttranslational processing of gastrin. , 1989, Physiological reviews.

[106]  R. Hill,et al.  Effects of cholecystokinin and related peptides on neuronal activity in the ventromedial nucleus of the rat hypothalamus , 1988, British journal of pharmacology.

[107]  L. Rovati,et al.  Pharmacological properties of lorglumide as a member of a new class of cholecystokinin antagonists. , 1987, Arzneimittel-Forschung.

[108]  L. Rovati,et al.  Pharmacological characterisation of a new potent and specific nonpolypeptidic cholecystokinin antagonist. , 1987, Arzneimittel-Forschung.

[109]  Y. Iwamoto,et al.  CR‐1409: A Potent Inhibitor of Cholecystokinin‐Stimulated Amylase Release and Cholecystokinin Binding in Rat Pancreatic Acini , 1987, Pancreas.

[110]  R. Chang,et al.  Characterization of the binding of [3H]-(+/-)-L-364,718: a new potent, nonpeptide cholecystokinin antagonist radioligand selective for peripheral receptors. , 1986, Molecular pharmacology.

[111]  R. Deschenes,et al.  Cloning and sequence analysis of a cDNA encoding rat preprocholecystokinin. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[112]  S. Snyder,et al.  Distinct cholecystokinin receptors in brain and pancreas. , 1980, Proceedings of the National Academy of Sciences of the United States of America.

[113]  J. Vanderhaeghen,et al.  New peptide in the vertebrate CNS reacting with antigastrin antibodies , 1975, Nature.

[114]  V. Mutt,et al.  Structure of Porcine Cholecystokinin‐Pancreozymin , 1968 .

[115]  J. Morley Structure-function relationships in gastrin-like peptides , 1968, Proceedings of the Royal Society of London. Series B. Biological Sciences.

[116]  R. A. Gregory,et al.  The constitution and properties of two gastrins extracted from hog antral mucosa , 1964, Gut.

[117]  H. Raper,et al.  Pancreozymin, a stimulant of the secretion of pancreatic enzymes in extracts of the small intestine , 1943, The Journal of physiology.

[118]  A. Ivy,et al.  A HORMONE MECHANISM FOR GALL-BLADDER CONTRACTION AND EVACUATION , 1928 .

[119]  J. S. Edkins The chemical mechanism of gastric secretion. , 1905, The Journal of physiology.

[120]  G. Dockray,et al.  Gastrin: old hormone, new functions , 2004, Pflügers Archiv.

[121]  C. Garbay,et al.  Synthesis and biological characterisation of [3H]BBL454, a new CCK2 selective radiolabelled agonist displaying original pharmacological properties. , 2004, Bioorganic & medicinal chemistry letters.

[122]  R. Håkanson,et al.  Pharmacological analysis of CCK(2) receptor ligands using COS-7 and SK-N-MC cells, expressing the human CCK(2) receptor. , 2002, Regulatory peptides.

[123]  J. Williams,et al.  Intracellular signaling mechanisms activated by cholecystokinin-regulating synthesis and secretion of digestive enzymes in pancreatic acinar cells. , 2001, Annual review of physiology.

[124]  Y. Le Marchand-Brustel,et al.  Printed in U.S.A. Copyright © 1999 by The Endocrine Society Physiological Role of Cholecystokinin B/Gastrin , 1999 .

[125]  S. Rose,et al.  Second generation "peptoid" CCK-B receptor antagonists: identification and development of N-(adamantyloxycarbonyl)-alpha-methyl-(R)-tryptophan derivative (CI-1015) with an improved pharmacokinetic profile. , 1998, Journal of medicinal chemistry.

[126]  J. Rehfeld,et al.  Abnormal gastric histology and decreased acid production in cholecystokinin-B/gastrin receptor-deficient mice. , 1997, Gastroenterology.

[127]  B. Andersen Measurement and occurrence of sulfated gastrins. , 1984, Scandinavian journal of clinical and laboratory investigation. Supplementum.

[128]  I. Goldfine,et al.  Bioassay of plasma cholecystokinin in rats: effects of food, trypsin inhibitor, and alcohol. , 1984, Gastroenterology.

[129]  V. Mutt,et al.  Structure of porcine cholecystokinin-pancreozymin. 1. Cleavage with thrombin and with trypsin. , 1968, European journal of biochemistry.